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Abstract 
Introduction 
In clinical practice, non-steroidal anti-inflammatory drugs (NSAIDs) are commonly 
discontinued after response to biologic therapy is achieved in patients with axial 
spondyloarthritis (axSpA), but the impact of NSAID discontinuation has not been assessed in 
prospective controlled trials. The aim of the SPARSE study was to evaluate the effects of the 
anti–tumor necrosis factor agent etanercept on NSAID intake and conventional clinical 
outcomes in axSpA patients. 
Methods 
In the double-blind, placebo-controlled period, patients with active (mini Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) ≥4) axSpA despite optimal NSAID intake 
were randomized to receive etanercept 50 mg or placebo once weekly for 8 weeks. All 
patients were advised to taper/discontinue their NSAID intake during the treatment period. 
NSAID intake was self-reported by diary and Assessment of SpondyloArthritis International 
Society (ASAS)-NSAID scores calculated based on ASAS recommendations. The primary 
endpoint was change from baseline to week 8 in ASAS-NSAID score (analysis of 
covariance). 
Results 
In 90 randomized patients at baseline, mean age (standard deviation) was 38.9 (11.8) years; 
disease duration, 5.7 (8.1) years; 59/90 (66%) were human leukocyte antigen-B27 positive; 
51/90 (57%) had radiographic sacroiliitis; and 45/90 (50%) were magnetic resonance imaging 
sacroiliitis−positive. Mean ASAS-NSAID scores were similar between etanercept and 
placebo groups at baseline (98.2 (39.0) versus 93.0 (23.4)), as were BASDAI (6.0 (1.7) 
versus 5.9 (1.5)), and Bath Ankylosing Spondylitis Functional Index (5.2 (2.1) versus 5.1 
(2.2)). Mean changes (SE) in ASAS-NSAID score from baseline to week 8 were –63.9 (6.1) 
and –36.6 (5.9) in the etanercept and placebo groups (between-group difference, –27.3; P = 
0.002). Significantly higher proportions of patients receiving etanercept versus placebo had 
an ASAS-NSAID score <10 (46% versus 17%; P = 0.008) and ASAS-NSAID score of 0 
(41% versus 14%; P = 0.013) at this time point. Significantly more patients in the etanercept 
versus placebo group achieved BASDAI50 (39% versus 18%; P = 0.032) and ASAS40 (44% 
versus 21%; P = 0.028) at week 8. 
Conclusions 
In patients with axSpA, etanercept was associated with clinically relevant NSAID-sparing 
effects in addition to significant improvements in conventional clinical outcomes. 
Trial registration 
ClinicalTrials.gov NCT01298531. Registered 16 February 2011. 
Introduction 
Spondyloarthritis (SpA) encompasses a cluster of rheumatic conditions, characterized by 
inflammation of the spine, entheses, and peripheral joints, that share an association with the 
major histocompatibility complex class 1 antigen (human leukocyte antigen (HLA)-B27) and 
with clinical extra-articular manifestations, such as inflammatory bowel disease, psoriasis, 
and uveitis [1]. Classification criteria of the Assessment of SpondyloArthritis International 
Society (ASAS) distinguish between predominantly axial and peripheral disease 
manifestations. Patients with back pain persisting for longer than 3 months and symptom 
onset before 45 years of age are classified as having axial SpA (axSpA) if they have evidence 
of sacroiliitis on imaging (i.e. structural damage observed on plain x-rays or inflammatory 
lesions observed on magnetic resonance imaging (MRI)) in addition to at least one SpA 
feature (satisfying criteria for the “imaging arm”), or, in the absence of imaging evidence of 
sacroiliitis, if they have HLA-B27 positivity and at least two SpA features (satisfying criteria 
for the “clinical arm”) [2]. Patients with axSpA on imaging and non-radiographic axSpA 
have shown a similar burden of illness, with comparable levels of disease activity and pain, 
as well as functional and quality-of-life impairment [3-5]. 
Since the beginning of the new millennium, the introduction of biologic agents for use in 
persistent disease has transformed the SpA treatment paradigm. Despite these important 
developments, non-steroidal anti-inflammatory drugs (NSAIDs) continue to serve as first-line 
pharmacotherapy, particularly for axSpA [6,7]. In fact, a good response to NSAID therapy is 
one of the SpA features included in candidate criteria for both the imaging and clinical arms 
of the ASAS axSpA classification [2]. NSAIDs effectively reduce pain and stiffness in 
patients with SpA after 2 to 3 days [8-10] and also may reduce levels of biological 
inflammatory markers [11]. In addition, some data suggest that NSAIDs reduce progression 
of structural damage [12-14]. However, the symptomatic, anti-inflammatory, and potential 
structural benefits of NSAIDs are dependent on their continuous daily use, which may be 
problematic because of gastrointestinal, cardiovascular, and renal toxicity associated with 
protracted therapy [15-19]. In light of safety concerns, national health agencies have 
recommended use of NSAIDs at the minimum effective dose for the shortest possible period 
[20,21]. 
Anti–tumor necrosis factor (TNF) agents have been shown to improve signs and symptoms in 
patients with still-active axSpA despite stable background NSAID therapy in controlled 
clinical trials [22-28]. In patients who respond to anti-TNF therapy, clinicians may advise 
continuation of systematic daily NSAID intake in combination with the biologic therapy 
because of the potential structural effects of NSAIDs and potential lack of structural effects 
of anti-TNF agents, with the aim of reducing long-term disability. A preliminary study 
suggests potential structural benefits of anti-TNF agents [29], but these observations need to 
be confirmed in additional clinical trials. Alternatively patients may be advised to discontinue 
NSAIDs once symptoms improve or disappear with anti-TNF therapy to avoid the possible 
complications of long-term NSAID intake. For many clinicians, the putative structural 
benefits of NSAIDs do not outweigh the risk of adverse effects. 
Although NSAID discontinuation after biologic response in axSpA patients may be common 
in the clinical practice setting [30], the impact of NSAID reduction or withdrawal has never 
been evaluated in a prospective randomized placebo-controlled trial in this population. The 
amount of NSAID intake has been proposed by the ASAS to be a clinically relevant outcome 
measure for clinical studies in axSpA to evaluate NSAID toxicity as well as the potential 
NSAID-sparing effects of other treatments [31]. The ASAS-NSAID scoring system [31] has 
recently been developed as a standardized method of evaluating NSAID intake in clinical 
trials. The aim of the present randomized, controlled study (SPARSE; ClinicalTrials.gov 
NCT01298531) was two-fold: first, to quantify the effects of treatment with the anti-TNF 
agent etanercept on NSAID intake in patients with axSpA using the ASAS-NSAID scoring 
method; and second, to evaluate the safety and efficacy of etanercept in improving the signs 
and symptoms of the disease. 
Methods 
Study design and study drug 
The 8-week, randomized, double-blind, placebo-controlled period of this two-period, 
multicenter, phase 4, prospective study commenced in May, 2011; the study was completed 
in April, 2013. All patients were enrolled and the study conducted in 19 centers in France. At 
the screening visit, investigators requested that patients discontinue their NSAID and restart 
the NSAID only if they experienced symptom flare, adjusting treatment as needed to provide 
optimal symptomatic control. Patients who remained asymptomatic without NSAID 
treatment during the 2- to 6-week screening period were considered ineligible and were 
withdrawn from the study. Patients who experienced a flare of symptoms after discontinuing 
their NSAID and had restarted NSAID treatment were randomized using an interactive voice 
response system (Impala) in a 1:1 ratio to receive either etanercept 50 mg or placebo 
subcutaneously once weekly for 8 weeks, in addition to their background NSAID. All 
patients were advised to taper/discontinue their NSAID intake during the study treatment 
period. 
Patients and physicians remained blinded to treatment assignment throughout the 8-week 
study period. Patients randomized to either treatment group were permitted to “early escape” 
to open-label etanercept 50 mg once weekly at week 4 if they experienced a >50% increase 
from baseline in total back pain or the Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) [32] despite receiving NSAIDs at the maximum tolerated dosage. All patients 
who completed the double-blind period were eligible to receive etanercept 50 mg once 
weekly plus background NSAID during a subsequent 8-week open-label treatment period. 
The study was conducted in accordance with the International Conference on Harmonization 
guidelines for good clinical practice and the Declaration of Helsinki. Study activities were not 
initiated until patients provided informed consent. The study was approved by the central 
independent review board of the Comité de Protection des Personnes Ile de France VIII, 
Hôpital Ambroise Paré 9, Avenue Charles de Gaulle, Boulogne Billancourt 92100, France 
(Chairperson: Dr. Frédérique Barthod). 
Inclusion/exclusion criteria 
Adult patients were eligible for the study if they had axial SpA, as defined by ASAS 
classification criteria [2]. Active axial involvement was required, defined by mini-BASDAI 
[33] ((Question 1+ Question 2+ (Question 5 + Question 6)/2)/3 ≥4 at screening and study 
baseline), with an inadequate response to at least two NSAIDs taken at the maximum 
tolerated doses (determined from medical history) for a total combined duration of more than 
1 month. Enrolled patients were required to have received an NSAID for at least 5 days per 
week at two-thirds the maximum licensed dosage for 4 weeks before screening and 1 week 
before baseline. Patients were ineligible if they received previous biologic treatment; >10 
mg/day of prednisone or equivalent (or changed dose) within 4 weeks of baseline; or an intra-
articular, intravenous, intramuscular, or subcutaneous corticosteroid within 6 weeks of 
screening. They were also excluded if they had uncontrolled inflammatory bowel disease or 
uveitis. 
Outcome measures 
Study data were collected in compliance with ASAS recommendations for clinical trials of 
SpA [34]. Imaging was read locally by the radiologist or rheumatologist providing care for 
the patient. The primary endpoint was the change from baseline to week 8 in the ASAS-
NSAID score [31], calculated based on NSAID intake recorded in patient diaries. The ASAS-
NSAID score takes into account the type of NSAID, the total daily dose, and number of days 
with intake during the period of interest (i.e. 7 days before the respective visit). 
A secondary measure of NSAID-sparing effects was the change in ASAS-NSAID score over 
time. Secondary clinical endpoints included the proportions of patients who achieved ASAS 
partial remission [35], BASDAI50 response [32]; ASAS20 and ASAS40 responses [36]; and 
patient acceptable symptom state (PASS) during the double-blind and open-label periods 
[37,38]. Mean scores over time for the BASDAI (0−10) [32]; Ankylosing Spondylitis Disease 
Activity Score on the basis of C-reactive protein (CRP) (ASDAS-CRP) [39]; Physician 
Global Assessment (PGA) of disease activity (0−10); total back pain; Bath Ankylosing 
Spondylitis Functional Index (BASFI; 0−10) [40]; and Bath Ankylosing Spondylitis 
Metrology Index (BASMI; 0−10) were also measured. Post hoc analyses were also conducted 
for the proportions of patients achieving other NSAID-sparing endpoints at week 8 (i.e. a 
50% decrease in ASAS-NSAID score compared to baseline, an ASAS-NSAID score <10, and 
an ASAS-NSAID score of 0); ASDAS-CRP inactive disease or moderate, high, or very high 
disease activity levels; and normal levels of CRP (i.e. ≤1.25 × upper limit of normal (4.9 
mg/L)) at week 8. Statistical analysis was not performed for the latter post hoc analyses. 
Sample size 
The sample size was determined based on the following assumptions for the primary 
endpoint: a mean ASAS-NSAID score of 100 in both groups at baseline, and mean scores of 
50 and 80 in the etanercept/etanercept and placebo/etanercept groups, respectively, at week 8. 
A target sample size of 39 patients per treatment group was estimated to provide a between-
group difference of 30 for change from baseline to week 8 in the ASAS-NSAID score, 
assuming a standard deviation of 40 and based on at least 90% statistical power and two-
sided testing at α = 0.05. 
Collected NSAID diary data 
The ASAS-NSAID score was calculated based on NSAID usage completed on diary cards. 
Patients were requested to record details of NSAID intake for every day of NSAID usage, 
including the NSAID name, the dose, and number of tablets taken each day. 
Statistical analyses 
Continuous baseline demographic and disease characteristic variables were summarized 
using descriptive statistics in the intent-to-treat (ITT) population, which comprised all 
randomized patients who received at least one dose of study drug. NSAID-sparing and 
clinical efficacy and safety analyses were also conducted in the ITT population unless 
otherwise noted. 
The primary endpoint was the change from baseline to week 8 in the ASAS-NSAID score in 
the ITT population. The ASAS-NSAID score was calculated from NSAID usage completed 
on the patient diary cards for the previous 7 days for a particular visit. Scores were calculated 
only if at least 5 of the 7 days were completed. Missing data were imputed based on adjacent 
data and using the last observation carried forward (LOCF) approach. Analysis of covariance 
(ANCOVA) was used for the primary analysis of the primary endpoint, with baseline ASAS-
NSAID score and treatment as explanatory variables. No adjustments were made for multiple 
testing. 
The primary analysis of the primary endpoint was repeated in the modified ITT (mITT) 
population as a sensitivity analysis; the mITT population encompassed all patients in the ITT 
population, but for ITT patients who entered the escape arm, only data collected for time 
points up until initiation of open-label treatment were used. An additional sensitivity analysis 
was conducted with Wilcoxon rank-sum tests stratified by baseline ASAS-NSAID score. 
Hodges–Lehmann confidence intervals (CIs) were calculated for the treatment difference 
corresponding to unstratified Wilcoxon rank-sum tests. In addition, a post hoc sensitivity 
analysis was performed using a different approach to missing data imputation. Specifically, 
when data were missing for a particular day in the diary, the missing data were counted as no 
intake; both an LOCF approach and a baseline observation carried forward (when no post-
baseline diary data were available) approach were used. ANCOVA was used in the same 
manner as in the primary analysis described above. 
The conventional clinical response outcomes at week 8, i.e. partial remission, BASDAI50, 
ASAS20 and ASAS40 responses, and PASS, were analyzed using a logistic regression 
model, including treatment and the corresponding baseline scores as covariates. The LOCF 
approach was used for all clinical response outcomes except PASS, for which observed cases 
were analyzed. These clinical responses were also summarized at weeks 4, 8, 12, and 16 of 
the double-blind and open-label periods using observed cases. Changes from baseline in 
continuous NSAID-sparing and clinical endpoints were analyzed using ANCOVA with 
treatment and the corresponding baseline score as covariates. The NSAID intake endpoints, 
i.e. a 50% decrease in ASAS-NSAID score compared to baseline, an ASAS-NSAID score 
<10, and an ASAS-NSAID score of 0, were analyzed using a logistic regression model 
including treatment and the baseline ASAS-NSAID score as covariates. Missing data were 
imputed as outlined for the primary endpoint. All statistical testing was two-sided and 
conducted at the 5% level; CIs were two-sided 95% CIs. 
Results 
Patients 
Of 128 screened patients, 90 patients (etanercept group, n = 42; placebo group, n = 48) were 
randomized into the 8-week double-blind treatment period and included in the ITT, mITT, 
and safety populations (Figure 1). Eight (19%) patients in the etanercept group and ten (21%) 
in the placebo group violated the NSAID inclusion criteria (i.e. NSAID intake for at least 5 
days/week at two-thirds the maximum licensed dosage during the week before the baseline 
visit). Fewer patients in the etanercept group early escaped during the double-blind period 
than in the placebo group (etanercept group, n = 6 (14%); placebo group, n = 11 (23%)). 
Eighty-one patients (etanercept group, n = 39; placebo group, n = 42) were included in the 
primary analysis of the primary endpoint. At baseline, one patient (2%) in the placebo group 
reported a missing NSAID diary; four patients (10%) in the etanercept group and 11 patients 
(23%) in the placebo group had some missing diary information. (A summary of missing 
NSAID diary data at baseline and during the double-blind period is provided in the 
Additional file 1: Table S1.) A total of 66 patients (etanercept group, n = 33; placebo group, n 
= 33) completed the double-blind period and entered the open-label treatment period. 
Figure 1 Patient flow through the double-blind and open-label phases. AE, adverse 
event; DB, double-blind; ETN, etanercept; OL, open-label; PBO, placebo. 
Demographic and disease characteristics at baseline were similar between the treatment 
groups (Table 1). Fifty-nine of 90 patients (66%) were HLA-B27 positive, 51/90 patients 
(57%) had radiographic sacroiliitis based on the modified New York criteria [41] and 45/90 
patients (50%) had sacroiliac joint inflammation on MRI based on the OMERACT (Outcome 
Measures in Rheumatology) definition [42]. At baseline, patients had a moderate to high 
level of disease activity and functional impairment as measured by BASDAI, ASDAS, and 
BASFI. A relatively low level of spinal mobility impairment was suggested by the low 
baseline BASMI. 
Table 1 Baseline demographics and disease characteristics 
Baseline characteristics Etanercept 50 mg/Etanercept 50 
mg 
Placebo/Etanercept 50 mg 
n = 42 n = 48 
Patient characteristics 
Age, years 38.8 (12.3) 38.9 (11.4) 
Female, n (%) 18 (42.9) 16 (33.3) 
White, n (%) 40 (95.2) 48 (100.0) 
Weight, kg 73.8 (14.2) 75.4 (15.2) 
Body mass index, kg/m2 25.7 (4.8) 25.9 (4.9) 
HLA-B27 positive, n (%) 28 (66.7) 31 (64.6) 
Disease characteristics 
Duration since diagnosis of ankylosing spondylitis, 
years 
6.0 (9.0) 5.5 (7.4) 
Past history or present symptoms, n (%)   
     Arthritis 11 (26.2) 18 (37.5) 
     Inflammatory back pain 40 (95.2) 48 (100.0) 
     Enthesitis 25 (59.5) 33 (68.8) 
     Dactylitis 4 (9.5) 8 (16.7) 
     Psoriasis 9 (21.4) 9 (18.8) 
     Uveitis 5 (11.9) 3 (6.3) 
Family history, n (%)   
     Ankylosing spondylitis 9 (21.4) 4 (8.3) 
     Rheumatoid arthritis 2 (4.8) 3 (6.3) 
     Inflammatory bowel disease 2 (4.8) 1 (2.1) 
     Uveitis 2 (4.8) 0 
Positive pelvic x-ray, n (%) 24 (57.1) 27 (56.3) 
MRI sacroiliitis positive, n (%) 21 (50.0) 24 (50.0) 
NSAID intake 
ASAS-NSAID score1 98.2 (39.0) 93.0 (23.4) 
Disease activity 
BASDAI (0–100) 6.0 (1.6) 5.9 (1.5) 
ASDAS-CRP 3.4 (0.9) 3.2 (0.8) 
ASDAS-CRP disease state2, n (%)   
     Inactive disease 0 0 
     Moderate disease activity 5 (11.9) 3 (7.0) 
     High disease activity 19 (45.2) 23 (53.5) 
     Very high disease activity 18 (42.9) 17 (39.5) 
PGA of disease activity (0–10) 6.4 (1.5) 6.2 (1.3) 
Total back pain (0–100) 6.7 (1.7) 6.4 (1.8) 
BASFI (0–100) 5.2 (2.1) 5.1 (2.2) 
BASMI (0–10) 2.6 (1.8) 2.6 (1.6) 
CRP level, mg/dL 1.0 (1.3) 0.9 (1.4) 
Normal CRP level3, n (%) 21 (50.0) 28 (65.1) 
Safety population; data are mean (standard deviation) (SD), unless otherwise specified. 
1Last observation carried forward, with imputation, intent-to-treat population. 
2Inactive disease = ASDAS-CRP <1.3; moderate disease activity = 1.3 ≤ ASDAS-CRP <2.1; high disease activity = 2.1 ≤ 
ASDAS-CRP <3.5; very high disease activity = ASDAS-CRP ≥3.5. 
3Normal CRP = ≤1.25 × the upper limit of normal (4.9 mg/L). 
MRI, magnetic resonance imaging; ASAS, Assessment of SpondyloArthritis International Society; NSAID, non-steroidal 
anti-inflammatory drug; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS-CRP, Ankylosing 
Spondylitis Disease Activity Score on the basis of CRP; PGA, Physician Global Assessment; BASFI, Bath Ankylosing 
Spondylitis Function Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein. 
NSAID-sparing effects 
For patients in the ITT population, the mean (SD) ASAS-NSAID score at baseline was 
similar between the two groups: 98.2 (39.0) and 93.0 (23.4) in the etanercept (n = 42) and 
placebo (n = 45) groups, respectively. The primary analysis of the primary endpoint showed a 
significant difference of –27.3 (95% CI: –44.2 to –10.4; P = 0.002) between the etanercept (n 
= 39) and placebo (n = 42) groups in the change from baseline in ASAS-NSAID score at 
week 8 (Figure 2A). 
Figure 2 NSAID-sparing effects. (A) Change in ASAS-NSAID score from baseline to week 
8 in patients in the etanercept and placebo groups (primary analysis of primary endpoint). 
ANCOVA, LOCF, with imputation of missing diary data, in the ITT population. (B) The 
proportion of patients in the etanercept and placebo groups achieving other NSAID-sparing 
endpoints at week 8 of the double-blind period. LOCF, with imputation, ITT population (n = 
number of patients achieving endpoint; N = number of patients with analyzable data). (C) 
Mean ASAS-NSAID scores (± SD) in the etanercept/etanercept and placebo/etanercept 
groups in the double-blind and open-label phases. ASAS-NSAID scores were calculated for 
observed cases, with no imputation of missing diary data. ASAS-NSAID, Assessment of 
SpondyloArthritis International Society non-steroidal anti-inflammatory drug use; ETN, 
etanercept; ITT, intent-to-treat; LOCF, last observation carried forward; PBO, placebo; SD, 
standard deviation; SE, standard error. 
Findings from the sensitivity analyses performed in the mITT population (etanercept, n = 39; 
placebo, n = 42) and with the Wilcoxon rank-sum test (etanercept, n = 39; placebo, n = 42) 
were consistent with those of the primary analysis, with differences of –27.8 (–44.8 to –10.8; 
P = 0.002) and –33.3 (Hodges–Lehmann CI: –50.0 to –11.4; P = 0.004), respectively. In the 
post hoc ANCOVA sensitivity analysis of the primary endpoint (etanercept, n = 42; placebo, 
n = 47), a similar statistically significant difference of –30.4 (–46.2 to –14.7; P = 0.0002) was 
found between the treatment groups. 
At week 8, significantly higher proportions of etanercept-treated patients achieved the 
NSAID-sparing endpoints of an ASAS-NSAID score <10 (P = 0.008) and an ASAS-NSAID 
score of 0 (P = 0.013; Figure 2B). Significant reductions in the ASAS-NSAID score were 
observed from baseline to week 16 in the etanercept/etanercept group (n = 25) and from week 
8 to week 16 in the placebo/etanercept (n = 17) group: –65.93 (–87.0 to –44.9; P <0.0001) 
and –39.2 (–52.9 to –25.5; P <0.0001), respectively (Figure 2C). 
Clinical efficacy 
In the double-blind period, a significantly greater proportion of patients in the etanercept 
group than in the placebo group achieved BASDAI50 and ASAS40 responses and PASS at 
week 8 (P <0.05; Figure 3A). Numerically greater proportions of patients receiving 
etanercept achieved all clinical efficacy endpoints compared with patients receiving placebo 
at weeks 4 and 8 of the double-blind period. At weeks 4 and 8 of the double-blind period, 
etanercept was associated with significantly greater improvement in most axSpA signs and 
symptoms compared with placebo, including ASDAS-CRP, PGA of disease activity, total 
back pain, and BASFI (Table 2). Although the difference between treatment groups in change 
from baseline to week 8 in BASDAI was not statistically significant at week 8 (P = 0.051), 
the difference was significant at week 4 (P = 0.015). No significant difference in BASMI was 
observed between the etanercept and placebo groups at weeks 4 or 8. 
Figure 3 Clinical efficacy. (A) The proportion of patients in the etanercept and placebo 
groups achieving clinical endpoints at week 8 of the double-blind period. Logistic regression, 
LOCF (except PASS, which was calculated in observed cases). (B) The proportion of patients 
in the etanercept and placebo groups achieving ASDAS-CRP disease activity states at week 8 
of the double-blind period. Post hoc analysis of ITT population; n = number of patients with 
non-missing ASDAS-CRP results at each visit. Inactive disease = ASDAS-CRP <1.3; 
moderate disease activity = 1.3 ≤ ASDAS-CRP <2.1; high disease activity = 2.1 ≤ ASDAS-
CRP <3.5; very high disease activity = ASDAS-CRP ≥3.5. ASAS, Assessment of 
SpondyloArthritis International Society; ASDAS-CRP, Ankylosing Spondylitis Disease 
Activity Score based on C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease 
Activity Index; ITT, intent-to-treat; LOCF, last observation carried forward; PASS, patient 
acceptable symptom state. 
Table 2 Absolute changes from baseline (week 0) to weeks 4 and 8 by treatment group (ITT, LOCF) 
Parameter Week 4 Week 8 
Etanercept 50 mg Placebo P- Etanercept 50 mg Placebo P- 
n = 39 n = 44 Value n = 41 n = 45 Value 
ASAS-NSAID Score 50.3 (6.7) 61.0 (6.5) 0.256 32.4 (6.1) 59.7 (5.9) 0.002 
Change from BL –46.3 (6.7) –35.6 (6.5) –63.9 (6.1) –36.6 (5.9) 
(95% CI) (–59.8, –32.9) (–48.5, –22.7) (–76.0, –51.8) (–48.3, –24.9) 
BASDAI (0–100) 4.5 (0.3) 5.4 (0.3) 0.015 4.0 (0.3) 4.8 (0.3) 0.051 
Change from BL –1.5 (0.3) –0.6 (0.3) –2.0 (0.3) –1.1 (0.3) 
(95% CI) (–2.0, –0.9) (–1.1, –0.0) (–2.7, –1.4) (–1.7, –0.5) 
ASDAS-CRP 2.4 (0.1) 3.1 (0.1) <0.0001 2.1 (0.1) 2.8 (0.1) 0.001 
Change from BL –0.9 (0.1) –0.2 (0.1) –1.2 (0.1) –0.5 (0.1) 
(95% CI) (–1.2, –0.7) (–0.4, 0.1) (–1.5, –0.9) (–0.8, –0.2) 
PGA of disease activity (0–10) 4.2 (0.3) 5.6 (0.3) 0.002 3.6 (0.4) 4.7 (0.3) 0.023 
Change from BL –2.0 (0.3) –0.7 (0.3) –2.7 (0.3) –1.6 (0.3) 
(95% CI) (–2.6, –1.5) (–1.3, –0.1) (–3.4, –2.0) (–2.2, –0.9) 
Total back pain (0–100 mm) 5.0 (0.4) 6.0 (0.3) 0.047 4.3 (0.4) 5.6 (0.4) 0.021 
Change from BL –1.6 (0.4) –0.6 (0.3) –2.2 (0.4) –1.0 (0.4) 
(95% CI) (–2.3, –0.9) (–1.3, 0.1) (–3.0, –1.5) (–1.7, –0.2) 
BASFI (0–100) 4.0 (0.3) 4.9 (0.2) 0.024 3.5 (0.3) 4.4 (0.3) 0.030 
Change from BL –1.1 (0.3) –0.3 (0.2) –1.7 (0.3) –0.8 (0.3) 
(95% CI) (–1.6, –0.6) (–0.8, 0.2) (–2.3, –1.1) (–1.3, –0.2) 
BASMI (0–10) 2.3 (0.2) 2.7 (0.2) 0.160 2.2 (0.2) 2.5 (0.2) 0.300 
Change from BL –0.3 (0.2) 0.1 (0.2) –0.4 (0.2) –0.1 (0.2) 
(95% CI) (–0.7, 0.1) (–0.3, 0.4) (–0.8, 0.0) (–0.5, 0.3) 
Data are adjusted mean (SE). ANCOVA model on change from baseline, with baseline value as a covariate and treatment as a factor. For ASAS-NSAID scores, only patients 
with non-missing change from baseline values were included for post-baseline visits. 
ITT, intent-to-treat population; LOCF, last observation carried forward; ASAS-NSAID, Assessment of SpondyloArthritis International Society non-steroidal anti-
inflammatory drug use; BL, baseline; CI; confidence interval; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; ASDAS-CRP, Ankylosing Spondylitis Disease 
Activity Score based on C-reactive protein; PGA, Physician Global Assessment; BASFI, Bath Ankylosing Spondylitis Function Index; BASMI, Bath Ankylosing Spondylitis 
Metrology Index; SE, standard error. ANCOVA, analysis of covariance. 
At week 8, 20% and 13% of patients in the etanercept and placebo groups, respectively, 
achieved ASDAS-CRP inactive disease, whereas 37% and 13% of patients in these groups 
had ASDAS-CRP moderate disease activity at week 8 (Figure 3B). Normal CRP levels were 
observed in 50% and 65% of patients receiving etanercept and placebo at baseline and in 
95% and 57% at week 8. Throughout the open-label period, response rates increased for most 
clinical efficacy endpoints, with steeper increases observed in the placebo/etanercept group 
than in the etanercept/etanercept group (Additional file 2: Figure S1). At week 16, 54% and 
57% of patients treated with etanercept in both the double-blind and open-label periods 
achieved BASDAI50 and ASAS40 responses, respectively; 49% and 56% of patients who 
received placebo for 8 weeks followed by etanercept for 8 weeks achieved these responses. 
As seen with the clinical efficacy endpoints, mean improvements in axSpA signs and 
symptoms increased further from weeks 8 to 16, with the most pronounced improvements in 
the placebo/etanercept group. 
Safety 
In the double-blind period, treatment-emergent adverse events (AEs) were reported in 81% 
and 54% of patients in the etanercept and placebo groups, respectively (Table 3). The most 
common AEs during this period in the etanercept group were rhinitis (12%); asthenia, 
hypercholesterolemia, injection site hypersensitivity, and injection site reactions (7% each); 
and headache, injection site erythema, and rash (5%). The most common AEs in the placebo 
group were asthenia and abdominal pain (6% each); and rhinitis, hypertension, injection site 
pruritus, alopecia, diarrhea, and pruritus (4% each). A serious AE was reported in one patient 
in the etanercept group (i.e. duodenitis) and two patients in the placebo group (i.e. traffic 
accident and chest pain). 
Table 3 Summary of treatment-emergent adverse events in the etanercept and placebo groups 
 No. of Patients (%) 
Double Blind (Week 8) Open Label (Week 16) Escape Arm 
Finding Etanercept 50 mg Placebo Etanercept 50 mg/Etanercept 
50 mg 
Placebo/Etanercept 50 mg Etanercept 50 mg/Etanercept 50 mg Placebo/Etanercept 50 mg 
n = 42 n = 48 n = 31 n = 33 n = 6 n = 11 
Any adverse event 34 (81.0) 26 (54.2) 12 (38.7) 17 (51.5) 6 (100.0) 9 (81.8) 
Serious adverse event 1 (2.4) 2 (4.2) 0 1 (3.0) 0 0 
Adverse event leading to 
discontinuation 
4 (9.5) 0 0 2 (6.1) 1 (16.7) 0 
Infections 11 (26.2) 10 (20.8) 6 (19.4) 8 (24.2) 2 (33.3) 4 (36.4) 
Serious infections 0 0 0 0 0 0 
In the open-label period, AEs were reported in 39% and 52% of patients in the 
etanercept/etanercept and placebo/etanercept groups, respectively. The most common AEs in 
the etanercept/etanercept group were headache, injection site pruritus, migraine, and oral 
herpes (6% each), and in the placebo/etanercept group, injection site erythema (12%), 
injection site reaction (9%), and headache, nasopharyngitis, and pharyngitis (6% each). One 
patient in the etanercept/etanercept group had a serious AE (i.e. cholecystitis). 
AEs of special interest, including infections, were reported in similar proportions of patients 
in the etanercept and placebo groups. No cases of tuberculosis, demyelinating disorders, 
malignancies, or deaths were reported. No significant changes from baseline to week 4 or 
week 8 in diastolic or systolic blood pressure were observed in either the etanercept or 
placebo group; differences between treatment groups in blood pressure changes were also not 
significant in the double-blind period. Finally, minimal changes in weight were seen in 
patients receiving etanercept/etanercept and placebo/etanercept during the double-blind and 
open-label periods. 
Discussion 
Etanercept was associated with NSAID-sparing effects in this prospective, randomized, 
placebo-controlled study, which was specifically conducted to test this efficacy outcome. The 
primary outcome measure was recommended by ASAS (e.g. ASAS-NSAID score based on 
NSAID category and daily dose intake) [31]. Importantly, despite the fact that more patients 
were able to reduce their NSAID intake in the etanercept group, this study also showed the 
clinically relevant symptomatic effects of etanercept versus placebo. 
To our knowledge, this double-blind, placebo-controlled study is the first to evaluate the 
NSAID-sparing effect of an anti-TNF agent using the ASAS-NSAID score as the primary 
endpoint. Because of the innovative design of this study, and despite the observed statistically 
significant difference, estimation of the clinical relevance of the observed results is 
challenging. In a previous clinical trial in which the ASAS-NSAID score was evaluated as an 
outcome measure, a change from baseline in ASAS-NSAID score of –24 after open-label 
anti-TNF therapy was considered to be clinically relevant [43]. The design and in particular 
the sample size of the present study was elaborated by defining a between-group difference in 
ASAS-NSAID score of 30 as clinically relevant. The between-group differences in this score 
observed in primary and secondary and post hoc sensitivity analyses (i.e. –27.3, –27.8, –33.3, 
and –30.4) closely approximate the anticipated difference, suggesting that the study’s 
statistically significant results are also clinically relevant. Moreover, to further evaluate 
clinical relevance, post hoc analyses of binary endpoints were performed at week 8, including 
the proportions of patients achieving a 50% reduction in ASAS-NSAID score and very low 
ASAS-NSAID scores (i.e. <10 and 0). Findings of these analyses also support the clinically 
significant NSAID-sparing effect of etanercept over placebo. 
Because patients were advised to decrease their NSAID intake during the treatment period 
and more patients in the etanercept group were found to have substantially reduced their 
NSAID intake, a lesser treatment effect of etanercept compared with placebo could 
reasonably have been expected for conventional outcome measures such as ASAS responses. 
In fact, in addition to the NSAID-sparing effect of etanercept, this study also demonstrated a 
symptomatic treatment effect of etanercept over placebo similar to that observed in 
“conventional” clinical trials in which NSAID intake was mandatory at baseline and stable 
NSAID levels were required during the double-blind period. For example, such 
“conventional” methodology was followed in the SPINE trial, which assessed the efficacy of 
etanercept versus placebo in patients with radiographic axSpA who were recruited in similar 
centers as those participating in the present study [44]. In the SPINE trial, 44% versus 23% of 
patients receiving etanercept versus placebo, respectively, achieved an ASAS40 response 
after 12 weeks, whereas in the SPARSE study, 44% versus 21% of patients receiving 
etanercept versus placebo achieved this endpoint after 8 weeks. Also noteworthy, and 
consistent with other clinical trials,[44,45] the ASDAS demonstrated greater discriminant 
capacity than the BASDAI in detecting the treatment effect of etanercept in the SPARSE 
study, as a significant difference was observed between etanercept and placebo at week 8 
with the former, but not the latter, measure. 
The present study has several noteworthy strengths and weaknesses. The main strength is its 
design (e.g. prospective, randomized, double-blind, placebo-controlled study) with the 
NSAID-sparing effect specified as the primary objective. The short duration of the study’s 
double-blind, placebo-controlled period may be considered a weakness. The 8-week duration 
was selected as it was considered sufficient to demonstrate the NSAID-sparing effect of the 
biologic agent while limiting the duration of exposure to placebo in patients with this painful, 
disabling condition. However, the magnitude of such treatment effect would likely have been 
greater in a longer trial; as noted in international ASAS recommendations, response rates in 
patients with axSpA treated with anti-TNF agents have been shown to plateau at and after 12 
weeks in phase III clinical trials.[46] Another weakness of the study involved protocol 
violations related to NSAID intake, which were mainly attributed to investigators’ difficulty 
in ensuring that enrolled patients had taken NSAIDs for at least 5 days at two-thirds the 
maximum licensed dosage in the week before the baseline visit. In future studies, 
investigators may be provided with a calculator or access to an electronic system during 
screening to improve their ability to check such eligibility criteria. The amount of missing 
data in patients’ diaries may also be perceived as a weakness. When the study protocol was 
designed, the optimal means of data collection, either by patient diary or physician interview, 
was the subject of debate. Given the shortcomings of patient collection using paper diaries 
encountered in this study (i.e. missing data), and the avoidance of such shortcomings in the 
German Spondyloarthropathy Inception Cohort (GESPIC) [47] and Outcome of Recent 
Undifferentiated Spondyloarthritis (DESIR) [48] cohort studies, which relied on physician 
interviews, electronic patient diaries or investigator collection may be considered stronger 
options in future studies. 
Evaluation of the safety profile of etanercept was not the main objective of this study, but no 
new information was revealed in this area. The study duration was too short to allow 
evaluation of potential benefits associated with the reduction in NSAID intake in etanercept-
treated patients. The observed reductions in NSAID dosage are likely to be more clinically 
relevant if extended long term; whether such reductions achieved over 8 weeks are clinically 
relevant has not yet been shown. In particular, no difference was observed in weight or blood 
pressure changes between the etanercept and placebo groups. 
Conclusions 
In this population of patients with axSpA who participated in the SPARSE trial, treatment 
with etanercept was associated with clinically relevant NSAID-sparing effects, which 
coincided with significant improvements in conventional clinical outcomes. Additional 
studies are required to further evaluate the ASAS-NSAID score as a meaningful outcome 
measure. Long-term observational cohorts are specifically needed to estimate the relationship 
between NSAID intake and AEs such as renal failure, but other studies are necessary as well 
to determine the optimal means of presenting the obtained results, such as using the ASAS-
NSAID score as a continuous or a binary variable. 
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Additional file 1: Table S1. Summary of missing NSAID diary data at baseline and during the double-blind period.
Intention-to-treat population (793k)
http://arthritis-research.com/content/supplementary/s13075-014-0481-5-s1.pdf
Additional file 2: Figure S1. The proportion of patients in the etanercept/etanercept and placebo/etanercept groups
achieving clinical endpoints during the double-blind and open-label periods: (A) ASAS partial remission; (B) BASDAI50
response; (C) ASAS20 response; (D) ASAS40 response; and (E) PASS. Observed cases. ASAS, Assessment of
SpondyloArthritis International Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; PASS, patient
acceptable symptom state (183k)
http://arthritis-research.com/content/supplementary/s13075-014-0481-5-s2.doc
